Should hepatitis B vaccine be used for infants?

Expert Review of Vaccines

Volumn 6, Issue 1, 2007, Pages 29-33

  Mansoor, Osman David ^a   Salama, Peter ^a  

^a UNITED NATIONS   (United States)

Author keywords

Anticancer vaccine; Hepatitis B vaccine; Infant immunization; Thimerosal

Indexed keywords

DIPHTHERIA TETANUS PERTUSSIS HEPATITIS B HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA TETANUS PERTUSSIS HEPATITIS B VACCINE; DIPHTHERIA TETANUS PERTUSSIS POLIO HEPATITIS B HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MERCURY; PRESERVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHILD CARE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INFANT; INFECTION RISK; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SCREENING; VACCINATION; VACCINATION REACTION; VERTICAL TRANSMISSION;

AGE FACTORS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INFANT; WORLD HEALTH;

EID: 33846897813     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.1.29     Document Type: Article

References (32)

1. Goldstein ST, Zhou F, Hadler SC et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34(6), 1329-1339 (2005).
2. World Health Organization. Hepatitis B vaccines. WHO position paper. Wkly Epidemiol. Rec. 79(28), 255-263 (2004).
3. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61, 1942-1956 (1988).
4. Hsieh CC, Tzonou A, Zavitsanos X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. Am. J. Epidemiol. 136, 1115-1121 (1992).
5. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2, 37 (2002).
6. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. NY Acad. Sci. 963, 13-20 (2002).
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006).
8. Blumberg BS. Australia antigen and the biology of hepatitis B. Nature 197, 17-24 (1997).
9. West DJ, Calandra GB, Hesley TM, Ioli V, Miller WJ. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine 11(Suppl. 1), S21-S27 (1993).
10. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336, 1855-1859 (1997).
11. Goh KT. Prevention and control of hepatitis B virus infection in Singapore. Ann. Acad. Med. Singapore 26, 671-681 (1997).
12. DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev. Vaccines 1(4), 461-466 (2002).
13. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J. Med. Virol. 44(2), 144-151 (1994).
14. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Br. Med. J. 332(7537), 328-336 (2006).
15. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355, 561-565 (2000).
16. Fitzsimons D, Francois G, Hall A et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 23(32), 4158-4166 (2005).
17. Cutts FT, Hall AJ. Vaccines for neonatal viral infections: hepatitis B vaccine. Expert Rev. Vaccines 3(4), 349-352 (2004).
18. Edmunds WJ, Medley GF, Nokes DJ et al. The influence of age on the development of the hepatitis B carrier state. Proc. R. Soc. Lond. B. Biol. Sci. 253, 197-201 (1993).
19. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 151, 599-603 (1985).
20. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. Br. Med. J. 329(7474), 1080-1086 (2004).
21. WHO. Meeting on hepatitis B control through immunization. Tokyo, Japan, 26-28 June, 2002.
22. Anonymous. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40(RR-13), 1-25 (1991).
23. Gilca V, Duval B, Boulianne N, Dion R, De Serres G. Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. Pediatr. Infect. Dis J. 25(4), 372-374 (2006).
24. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ. 9(1), 19-35 (2000).
25. Gregson AL, Edelman R. Does antigenic overload exist? The role of multiple immunizations in infants. Immunol. Allergy Clin. North Am. 23(4), 649-664 (2003).
26. Offit PA, Quarles J, Gerber MA et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 109(1), 124-129 (2002).
27. American Academy of Pediatrics, Public Health Service. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR 48, 563-565 (1999).
28. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114(3), 793-804 (2004).
29. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 118(1), e139-e150 (2006).
30. Expanded Programme on Immunization. Global Advisory Group - Part I. Wkly Epidemiol. Rec. 67, 11-15 (1992).
31. World Health Organization web site www.who.int/immunization/topics/ hepatitis_b/en/
32. WHO and UNICEF. Global immunization vision and strategy, 2006-2015 [WHO/IVB/05.05]. WHO, Geneva, Switzerland (2005) www.who.int/immunization/givs/ en/index.html